2 results
Approved WMOCompleted
Studies to date have demonstrated a reduction in HF-related hospitalizations and improved quality of life in patients using the CardioMEMS HF System when compared with patients receiving standard of care in the United States. The purpose of this…
Approved WMOCompleted
To determine if emixustat hydrochloride (emixustat) reduces the rate of progression of macular atrophy (MA) compared to placebo in subjects with Stargardt disease (STGD)1. To evaluate the safety and tolerability of emixustat compared to placebo2. To…